34
Participants
Start Date
September 30, 2004
Primary Completion Date
August 31, 2008
Study Completion Date
September 30, 2008
bevacizumab
10mg/kg, slow IV infusion, Days 1 and 14
erlotinib hydrochloride
150mg PO qd
fluorescence in situ hybridization
Targeting multiple genetic aberrations in isolated tumor cells.
gene expression analysis
gene expression analysis
immunologic technique
immunologic technique
laboratory biomarker analysis
laboratory biomarker analysis
biopsy
biopsy
Vanderbilt-Ingram Cancer Center at Franklin, Nashville
Sarah Cannon Research Institute, Nashville
Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville
Vanderbilt-Ingram Cancer Center, Nashville
National Cancer Institute (NCI)
NIH
Vanderbilt-Ingram Cancer Center
OTHER